These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 34707573)

  • 1. Role of Neutrophils in the Pathogenesis of Nonalcoholic Steatohepatitis.
    Hwang S; Yun H; Moon S; Cho YE; Gao B
    Front Endocrinol (Lausanne); 2021; 12():751802. PubMed ID: 34707573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-22 Ameliorates Neutrophil-Driven Nonalcoholic Steatohepatitis Through Multiple Targets.
    Hwang S; He Y; Xiang X; Seo W; Kim SJ; Ma J; Ren T; Park SH; Zhou Z; Feng D; Kunos G; Gao B
    Hepatology; 2020 Aug; 72(2):412-429. PubMed ID: 31705800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of neutrophils in innate immunity-driven nonalcoholic steatohepatitis: lessons learned and future promise.
    Wu L; Gao X; Guo Q; Li J; Yao J; Yan K; Xu Y; Jiang X; Ye D; Guo J
    Hepatol Int; 2020 Sep; 14(5):652-666. PubMed ID: 32880077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J
    Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis.
    van der Windt DJ; Sud V; Zhang H; Varley PR; Goswami J; Yazdani HO; Tohme S; Loughran P; O'Doherty RM; Minervini MI; Huang H; Simmons RL; Tsung A
    Hepatology; 2018 Oct; 68(4):1347-1360. PubMed ID: 29631332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Lee C; Kim J; Jung Y
    Cells; 2019 Oct; 8(10):. PubMed ID: 31619023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histopathological findings of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Kage M; Aishima S; Kusano H; Yano H
    J Med Ultrason (2001); 2020 Oct; 47(4):549-554. PubMed ID: 33136250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging Roles of T Cells in the Pathogenesis of Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
    Hirsova P; Bamidele AO; Wang H; Povero D; Revelo XS
    Front Endocrinol (Lausanne); 2021; 12():760860. PubMed ID: 34777255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
    Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
    Ota T
    Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Involvement of the Free Fatty Acid Receptor GPR120/FFAR4 in the Development of Nonalcoholic Steatohepatitis].
    Nakamoto K; Tokuyama S
    Yakugaku Zasshi; 2019; 139(9):1169-1175. PubMed ID: 31474633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apoptosis and non-alcoholic fatty liver diseases.
    Kanda T; Matsuoka S; Yamazaki M; Shibata T; Nirei K; Takahashi H; Kaneko T; Fujisawa M; Higuchi T; Nakamura H; Matsumoto N; Yamagami H; Ogawa M; Imazu H; Kuroda K; Moriyama M
    World J Gastroenterol; 2018 Jul; 24(25):2661-2672. PubMed ID: 29991872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid mediators of liver injury in nonalcoholic fatty liver disease.
    Liangpunsakul S; Chalasani N
    Am J Physiol Gastrointest Liver Physiol; 2019 Jan; 316(1):G75-G81. PubMed ID: 30383414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of Interleukin-8 Promotes the Progression of Fatty Liver to Nonalcoholic Steatohepatitis in Mice.
    Cho YE; Kim Y; Kim SJ; Lee H; Hwang S
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis.
    Yang YY; Xie L; Zhang NP; Zhou D; Liu TT; Wu J
    Acta Pharmacol Sin; 2022 May; 43(5):1180-1190. PubMed ID: 35190696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The common marmoset as a model for the study of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Kramer JA; Grindley J; Crowell AM; Makaron L; Kohli R; Kirby M; Mansfield KG; Wachtman LM
    Vet Pathol; 2015 Mar; 52(2):404-13. PubMed ID: 24913270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model.
    Tamura YO; Sugama J; Iwasaki S; Sasaki M; Yasuno H; Aoyama K; Watanabe M; Erion DM; Yashiro H
    J Pharmacol Exp Ther; 2021 Nov; 379(3):280-289. PubMed ID: 34535562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis.
    Pejnovic N; Jeftic I; Jovicic N; Arsenijevic N; Lukic ML
    World J Gastroenterol; 2016 Nov; 22(44):9706-9717. PubMed ID: 27956794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.